Chronic Lymphocytic Leukemia


Upon viewing this session, you will be able to:

• review evidence based frontline treatment regimens for CLL
• describe predictive value of undetectable MRD remissions in CLL
• assess relative risks and benefits of monotherapy vs. combination therapy of novel agents and how relative benefit differs amongst CLL patients with different prognostic biomarkers
• distinguish CLL progression on novel agents from Richter’s transformation
• describe emerging therapies for Ibrutinib failure and Richter’s transformation


  • Nitin Jain


Member Type Price
List Price $30.00
Active, International, Emeritus, and Honorary Members $20.00
Associate, International Associate, Student, and Resident Members $20.00
back to top